Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DVAXNASDAQ:INVANASDAQ:KERXNASDAQ:MNKD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDVAXDynavax Technologies$9.91-0.3%$10.21$9.22▼$14.63$1.19B1.062.17 million shs4.83 million shsINVAInnoviva$19.96-2.1%$19.64$16.08▼$22.00$1.28B0.37691,582 shs3.00 million shsKERXKeryx Biopharmaceuticals$3.36$0.00$2.47▼$5.98$344.00M2.351.69 million shs2.60 million shsMNKDMannKind$3.76-0.3%$4.32$3.63▼$7.63$1.15B1.022.42 million shs9.45 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDVAXDynavax Technologies-0.30%-0.80%+4.32%-27.56%-10.07%INVAInnoviva-2.11%-4.95%+4.39%+9.79%+22.60%KERXKeryx Biopharmaceuticals0.00%0.00%0.00%0.00%0.00%MNKDMannKind-0.27%-0.27%-7.62%-25.25%-27.55%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDVAXDynavax Technologies4.5337 of 5 stars3.32.00.04.73.21.71.9INVAInnoviva4.2316 of 5 stars3.50.00.04.22.91.71.9KERXKeryx BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AMNKDMannKind2.985 of 5 stars3.61.00.00.02.41.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDVAXDynavax Technologies 2.50Moderate Buy$24.00142.18% UpsideINVAInnoviva 3.00Buy$55.00175.55% UpsideKERXKeryx Biopharmaceuticals 0.00N/AN/AN/AMNKDMannKind 3.29Buy$10.33174.82% UpsideCurrent Analyst Ratings BreakdownLatest KERX, INVA, DVAX, and MNKD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2025DVAXDynavax TechnologiesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$33.00 ➝ $31.004/17/2025DVAXDynavax TechnologiesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$12.00 ➝ $10.004/10/2025MNKDMannKindMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$12.004/9/2025MNKDMannKindMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDVAXDynavax Technologies$277.25M4.29$0.16 per share62.77$4.54 per share2.18INVAInnoviva$358.71M3.49$3.35 per share5.95$11.03 per share1.81KERXKeryx Biopharmaceuticals$60.64M5.67N/AN/A($0.12) per share-28.00MNKDMannKind$285.50M4.00$0.14 per share27.17($0.29) per share-12.97Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDVAXDynavax Technologies$27.31M-$0.52N/A20.22N/A-20.39%3.59%2.20%8/5/2025 (Estimated)INVAInnoviva$23.39M-$1.01N/A12.88N/A-16.15%15.77%8.41%7/29/2025 (Estimated)KERXKeryx Biopharmaceuticals-$163.44M-$0.88N/AN/AN/A-96.41%N/A-60.05%N/AMNKDMannKind$27.59M$0.1037.6016.35N/A10.12%-32.41%10.85%8/6/2025 (Estimated)Latest KERX, INVA, DVAX, and MNKD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025MNKDMannKind$0.03$0.04+$0.01$0.04$75.86 million$78.35 million5/7/2025Q1 2025INVAInnovivaN/A$0.25N/A-$0.74N/A$88.63 million5/6/2025Q1 2025DVAXDynavax Technologies$0.03-$0.11-$0.14-$0.77$70.01 million$68.16 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDVAXDynavax TechnologiesN/AN/AN/AN/AN/AINVAInnovivaN/AN/AN/AN/AN/AKERXKeryx BiopharmaceuticalsN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDVAXDynavax Technologies0.4911.9310.84INVAInnoviva0.402.482.30KERXKeryx BiopharmaceuticalsN/A2.211.19MNKDMannKindN/A2.362.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDVAXDynavax Technologies96.96%INVAInnoviva99.12%KERXKeryx Biopharmaceuticals69.00%MNKDMannKind49.55%Insider OwnershipCompanyInsider OwnershipDVAXDynavax Technologies2.98%INVAInnoviva2.25%KERXKeryx Biopharmaceuticals1.61%MNKDMannKind2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDVAXDynavax Technologies350120.08 million116.50 millionOptionableINVAInnoviva10062.78 million61.36 millionOptionableKERXKeryx BiopharmaceuticalsN/A102.38 millionN/AOptionableMNKDMannKind400303.93 million295.73 millionOptionableKERX, INVA, DVAX, and MNKD HeadlinesRecent News About These CompaniesMannKind (NASDAQ:MNKD) Rating Lowered to Hold at Wall Street Zen5 hours ago | americanbankingnews.comMannKind (NASDAQ:MNKD) Rating Lowered to "Hold" at Wall Street ZenJune 27 at 12:09 AM | marketbeat.comHealth Rounds: Inhaled insulin as good as injection for children at mealtimeJune 25 at 3:29 PM | reuters.comMannKind (NASDAQ:MNKD) Stock Price Down 5.6% - What's Next?June 25 at 12:13 PM | marketbeat.comLeerink Partners Slashes MannKind Corporation’s (MNKD) Price Target to $7, Keeps a Buy RatingJune 24, 2025 | insidermonkey.comMannKind Corporation (NASDAQ:MNKD) Receives Consensus Rating of "Buy" from BrokeragesJune 24, 2025 | americanbankingnews.comMannKind Corporation (NASDAQ:MNKD) Given Average Recommendation of "Buy" by BrokeragesJune 24, 2025 | marketbeat.comLeerink Partnrs Analysts Cut Earnings Estimates for MannKindJune 21, 2025 | americanbankingnews.comMannKind FY2026 EPS Forecast Decreased by Leerink PartnrsJune 19, 2025 | marketbeat.comMannKind (NASDAQ:MNKD) Reaches New 1-Year Low - Should You Sell?June 17, 2025 | marketbeat.comMannKind’s Afrezza: A Significantly Undervalued Investment Opportunity with Promising Clinical DataJune 16, 2025 | tipranks.comMannKind (NASDAQ:MNKD) Upgraded by Wall Street Zen to "Buy" RatingJune 14, 2025 | marketbeat.comInsider Selling: MannKind Co. (NASDAQ:MNKD) Director Sells 64,085 Shares of StockJune 11, 2025 | insidertrades.comInsider Sell: Steven Binder Sells 64,085 Shares of MannKind Corp (MNKD)June 10, 2025 | gurufocus.comMannKind Co. (NASDAQ:MNKD) Director Sells 64,085 SharesJune 10, 2025 | marketbeat.comMannKind’s Strategic Growth Potential and Market Positioning: A Buy RecommendationJune 10, 2025 | tipranks.comMannKind (NASDAQ:MNKD) Sets New 1-Year Low - Time to Sell?June 10, 2025 | marketbeat.comCantor Fitzgerald Estimates MannKind FY2026 EarningsJune 10, 2025 | marketbeat.comMannKind Corp (MNKD) to Showcase Inhaled Insulin at ADA's 85th Scientific Sessions | MNKD stock newsJune 9, 2025 | gurufocus.comMannKind Corporation to Showcase Inhaled Insulin Innovations at ADA's 85th Scientific SessionsJune 9, 2025 | quiverquant.comQMannKind to present inhaled insulin study at ADA eventJune 9, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKERX, INVA, DVAX, and MNKD Company DescriptionsDynavax Technologies NASDAQ:DVAX$9.91 -0.03 (-0.30%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$9.91 0.00 (0.00%) As of 06/27/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.Innoviva NASDAQ:INVA$19.96 -0.43 (-2.11%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$19.96 0.00 (0.00%) As of 06/27/2025 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Keryx Biopharmaceuticals NASDAQ:KERXKeryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis. The company has strategic alliances with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of ferric citrate in Japan; and with Panion & BF Biotech, Inc. for the development and marketing of ferric citrate. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.MannKind NASDAQ:MNKD$3.76 -0.01 (-0.27%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$3.78 +0.02 (+0.40%) As of 06/27/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside QuantumScape Soars 30%: What Drove the Next-Gen EV Stock's Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
